Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies

Background: We evaluated the effects of low doses of the tyrosine kinase Abelson (Abl) inhibitor Nilotinib, on safety and pharmacokinetics in Parkinson’s disease dementia or dementia with Lewy bodies. Objectives: The primary outcomes of this study were safety and tolerability; pharmacokinetics and t...

Descripción completa

Detalles Bibliográficos
Autores principales: Pagan, Fernando, Hebron, Michaeline, Valadez, Ellen H., Torres-Yaghi, Yasar, Huang, Xu, Mills, Reversa R., Wilmarth, Barbara M., Howard, Hellen, Dunn, Connell, Carlson, Alexis, Lawler, Abigail, Rogers, Sean L., Falconer, Ramsey A., Ahn, Jaeil, Li, Zhaoxia, Moussa, Charbel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2016
Materias:
Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008228/
https://www.ncbi.nlm.nih.gov/pubmed/27434297
http://dx.doi.org/10.3233/JPD-160867

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008228/
https://www.ncbi.nlm.nih.gov/pubmed/27434297
http://dx.doi.org/10.3233/JPD-160867

Ejemplares similares